Lantern Pharma and Actuate Therapeutics Announce Research & Development Collaboration Leveraging Lantern’s Artificial Intelligence Platform

- Collaboration Will Leverage Lantern's RADR® A.I. Platform to Accelerate Development of Actuate's Drug Candidate, 9-ING-41 - Actuate's 9-ING-41 is a Best-In-Class Drug Candidate for Cancer & Fibrotic Diseases - Lantern Will Receive Equity Based on Meeting Development Milestones & May Receive Additional Equity Based on Use of Findings in Future Development

Daniel Carlson

May 3, 2021

Thank you for visiting Tailwinds Research. We are pleased to offer free research on select small and micro cap companies. It is free to join and we hope you’ll take the time to do so.

To create an account please click on this link.

If you already have an account, please log in here.

LEAVE A REPLY Cancel reply

DFC Advisory Services LLC (dba TW Research Group) is an investment adviser. We are also compensated for publishing information on certain companies. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Past performance is not indicative of future performance.